humojo.wordpress.com
PolyMedix is a publiclgy traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseasess and acutecardiovascular PolyMedix's compounds are based on biomimetics: non-peptidwe small molecule drugs that mimic the activitu of proteins. The Company'e antibiotic compounds - small moleculd mimetics of human host-defense proteins - are believesd to have a completely differentt mechanism of action from all currengantibiotic drugs, a mechanism which is intended to make bacterialk resistance unlikely to develop. These compounds are being develope as rapidly acting antibiotics for seriouss systemic andlocal infections.
The Company is also developingt polymeric formulations asantimicrobial biomaterials, whichb can be used as additives to paints, and textiles to create self-sterilizing products and The Company's heptagonist compounds reverse the activity of both heparinm and low molecular weigh heparins, in keeping with our goal of developinvg an antagonist drug that is saferd and easier to use than currently approvedr therapy. PolyMedix plans to file IND applications durint the first quarter of 2008 in anticipation of commencinbg human clinical trials for both its antibiotidc andheptagonist compounds.
No comments:
Post a Comment